What is Melanotan I?
Melanotan I (afamelanotide) is a synthetic analog of α-melanocyte stimulating hormone that selectively targets MC1 receptors to stimulate melanin production. While an
Melanotan I (Afamelanotide) — α-MSH analog for photoprotection
In short
Selective α-MSH analog studied for activating MC1R receptors and inducing melanogenesis in dermal models.
Overview
Melanotan I (afamelanotide) is a synthetic analog of α-melanocyte stimulating hormone that selectively targets MC1 receptors to stimulate melanin production. While an
Subcutaneous injection delivers Melanotan I directly into systemic circulation with 100% bioavailability. 30-minute half-life requires multiple daily injections for sustained MC1R activation and melanin production.
Molecular information
Research indications
Grouped by area. Each entry reflects a separate published hypothesis or clinical signal - not medical advice.
Registered in since 2014 as Scenesse for EPP treatment - only α-MSH analog with regulatory approval.
Melanotan I е изследователски пептид, който не е одобрен за консумация от хора и се предлага само за лабораторни цели. Започнете с по-ниски дози, за да оцените индивидуалната поносимост. Наблюдавайте бенките и промените по кожата чрез редовни самопрегледи. Използвайте стерилна техника на инжектиране, за да предотвратите инфекции. Поддържайте UV защита въпреки потъмняването на кожата, тъй като рискът от прекомерно излагане остава. Прекратете употребата при: тежко гадене, повръщане или стомашно-чревен дискомфорт, продължаващи над 24 часа. Следете за бързи промени в бенки, лунички или съществуващи пигментни лезии. Внимавайте за признаци на инфекция на мястото на инжектиране като продължително зачервяване, подуване, топлина или секреция. Необичайни кожни реакции включват обриви, копривна треска или силен сърбеж. Признаците на алергична реакция обхващат затруднено дишане, подуване на лицето и силно замайване.
4 peer-reviewed sources
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Scenesse approval
Phase 3 | 16 mg implant | 60 days | Reduced UV phototoxicity in EPP
NEJM · 2014
View the studyInformation about Melanotan I is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAdipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadEducation
No comments yet. Be the first.
Comments are reviewed before publishing.